Advances in the Study of CCT3 in Malignant Tumors: A Review

Overview

Journal Medicine (Baltimore)

Date 2025 Feb 10

PMID 39928781

Authors

Yun-Feng Bai

Xiao-Hui Shi

Mo-Lemei Zhang

Jia-Hui Gu

Ta-La Bai

Yin-Bao Bai

Affiliations

Soon will be listed here.

Abstract

Malignant tumors are among the leading causes of death worldwide, with their underlying mechanisms remaining largely unclear. Tumorigenesis is a complex process involving multiple factors, genes, and pathways. Tumor cells are characterized by abnormal proliferation, infiltration, invasion, and metastasis. Improving tumor diagnosis rates and identifying novel molecular therapeutic targets are of great significance for the advancement of modern medicine. Chaperonin containing TCP-1 subunit 3 (CCT3) is one of the subunits of the chaperonin containing TCP-1 complex, a molecular chaperone involved in protein folding and remodeling. CCT3 plays a crucial role in maintaining protein homeostasis, with key substrates including tubulin and actin. In recent years, CCT3 has been reported to be abnormally expressed in various cancers, correlating with prognosis and therapeutic outcomes. In this review, we summarize the basic structure and function of chaperonin containing TCP-1 complex and CCT3, and discuss the role of CCT3 in tumor development. Additionally, we explore its potential applications in cancer diagnosis and treatment.

References

Fernandes A, Viveros-Carreno D, Hoegl J, Avila M, Pareja R . Human papillomavirus-independent cervical cancer. Int J Gynecol Cancer. 2021; 32(1):1-7. DOI: 10.1136/ijgc-2021-003014. View

Luo L, Xie Q, Wu Y, Li P, Qin F, Liao D . Circular RNA CCT3 is a unique molecular marker in bladder cancer. BMC Cancer. 2023; 23(1):977. PMC: 10571266. DOI: 10.1186/s12885-023-11510-0. View

Dunn A, Melville M, Frydman J . Review: cellular substrates of the eukaryotic chaperonin TRiC/CCT. J Struct Biol. 2001; 135(2):176-84. DOI: 10.1006/jsbi.2001.4380. View

Vaddavalli P, Schumacher B . The p53 network: cellular and systemic DNA damage responses in cancer and aging. Trends Genet. 2022; 38(6):598-612. DOI: 10.1016/j.tig.2022.02.010. View

Betancourt Moreira K, Collier M, Leitner A, Li K, Lachapel I, McCarthy F . A hierarchical assembly pathway directs the unique subunit arrangement of TRiC/CCT. Mol Cell. 2023; 83(17):3123-3139.e8. PMC: 11209756. DOI: 10.1016/j.molcel.2023.07.031. View

Joly E, Tremblay E, Tanguay R, Wu Y . TRiC-P5, a novel TCP1-related protein, is localized in the cytoplasm and in the nuclear matrix. J Cell Sci. 1994; 107 ( Pt 10):2851-9. DOI: 10.1242/jcs.107.10.2851. View

Shi X, Cheng S, Wang W . Suppression of inhibits malignant proliferation of human papillary thyroid carcinoma cell. Oncol Lett. 2018; 15(6):9202-9208. PMC: 5958781. DOI: 10.3892/ol.2018.8496. View

Zhang Y, Wang Y, Wei Y, Wu J, Zhang P, Shen S . Molecular chaperone CCT3 supports proper mitotic progression and cell proliferation in hepatocellular carcinoma cells. Cancer Lett. 2016; 372(1):101-9. DOI: 10.1016/j.canlet.2015.12.029. View

Qu H, Zhu F, Dong H, Hu X, Han M . Upregulation of CCT-3 Induces Breast Cancer Cell Proliferation Through miR-223 Competition and Wnt/β-Catenin Signaling Pathway Activation. Front Oncol. 2020; 10:533176. PMC: 7541898. DOI: 10.3389/fonc.2020.533176. View

10.

Neiheisel A, Kaur M, Ma N, Havard P, Shenoy A . Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Int J Cancer. 2021; 150(5):727-740. DOI: 10.1002/ijc.33811. View

11.

Shi H, Zhang Y, Wang Y, Fang P, Liu Y, Li W . Restraint of chaperonin containing T-complex protein-1 subunit 3 has antitumor roles in non-small cell lung cancer via affection of YAP1. Toxicol Appl Pharmacol. 2022; 439:115926. DOI: 10.1016/j.taap.2022.115926. View

12.

Park J, Kim H, Gestaut D, Lim S, Opoku-Nsiah K, Leitner A . A structural vista of phosducin-like PhLP2A-chaperonin TRiC cooperation during the ATP-driven folding cycle. Nat Commun. 2024; 15(1):1007. PMC: 10837153. DOI: 10.1038/s41467-024-45242-x. View

13.

Monteith J, McMahon S . p53: the TRiC is knowing when to fold 'em. Mol Cell. 2013; 50(6):781-2. DOI: 10.1016/j.molcel.2013.06.009. View

14.

Huang J, Hu B, Yang Y, Liu H, Fan X, Zhou J . Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma. BMC Cancer. 2023; 23(1):241. PMC: 10012614. DOI: 10.1186/s12885-023-10677-w. View

15.

Duffy M, Synnott N, OGrady S, Crown J . Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2020; 79:58-67. DOI: 10.1016/j.semcancer.2020.07.005. View

16.

Caruso Bavisotto C, Alberti G, Vitale A, Paladino L, Campanella C, Rappa F . Hsp60 Post-translational Modifications: Functional and Pathological Consequences. Front Mol Biosci. 2020; 7:95. PMC: 7289027. DOI: 10.3389/fmolb.2020.00095. View

17.

Liu Y, Zhang X, Lin J, Chen Y, Qiao Y, Guo S . CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. Cell Death Dis. 2019; 10(9):644. PMC: 6733791. DOI: 10.1038/s41419-019-1894-5. View

18.

Ganesan P, Kulik L . Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2022; 27(1):85-102. DOI: 10.1016/j.cld.2022.08.004. View

19.

Huang X, Wang X, Cheng C, Cai J, He S, Wang H . Chaperonin containing TCP1, subunit 8 (CCT8) is upregulated in hepatocellular carcinoma and promotes HCC proliferation. APMIS. 2014; 122(11):1070-9. DOI: 10.1111/apm.12258. View

20.

Keenan J, Murphy L, Henry M, Meleady P, Clynes M . Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics. 2009; 9(6):1556-66. DOI: 10.1002/pmic.200800633. View